-
Stocks in Focus: Biocept (NASDAQ:BIOC), Geospace Technologies Corporation (NASDAQ:GEOS), Atmel Corporation (NASDAQ:ATML), Immunomedics Inc. (NASDAQ:IMMU), NRG Yield (NYSE:NYLD)
Biocept, Inc. (NASDAQ:BIOC) announced the launch of ROS1 testing on CTCs, which will help physicians identify which of their patients may be receptive to certain drugs for the treatment of non-small cell lung cancer. On Wednesday shares of Biocept, Inc. (NASDAQ:BIOC) closed at $2.52. Company’s EPS growth for next 5 years is recorded as 40.00%.…
-
Watch 5 Stocks: Immunomedics Inc. (NASDAQ:IMMU), CSX Corp. (NYSE:CSX), AllianceBernstein Holding L.P. (NYSE:AB), E-Commerce China Dangdang Inc. (NYSE:DANG), Waters Corporation (NYSE:WAT)
Immunomedics, Inc. (NASDAQ:IMMU) on 6 January announced that the FDA has issued a notice granting fast track status to the development program on its lead antibody-drug conjugate (ADC) candidate, sacituzumab govitecan. The company is evaluating sacituzumab govitecan for the treatment of triple-negative breast cancer (TNBC) in patients who have failed prior therapies for metastatic disease.…
-
Healthcare Gainers: Kite Pharma (NASDAQ:KITE), Juno Therapeutics Inc. (NASDAQ:JUNO), Clovis Oncology (NASDAQ:CLVS), Immunomedics Inc. (NASDAQ:IMMU), Mylan (NASDAQ:MYL)
On 6 January Kite Pharma, Inc. (NASDAQ:KITE) announced that the company has signed a “research collaboration and license agreement” with biotech giant Amgen Inc. (NASDAQ:AMGN) which will allow the company to develop cancer immunotherapy treatments. On Friday shares of Kite Pharma, Inc. (NASDAQ:KITE) closed at $82.66. On 14 January Juno Therapeutics Inc. (NASDAQ:JUNO) said that…
-
Best Stocks: Cliffs Natural Resources Inc. (NYSE:CLF), Immunomedics Inc. (NASDAQ:IMMU), AmSurg Corp. (NASDAQ:AMSG), Metro Bancorp (NASDAQ:METR), Celestica Inc. (NYSE:CLS)
An issue of Cliffs Natural Resources (NYSE:CLF) bonds rose 2.3% as a percentage of their face value during trading on Thursday, StockRatingsNetwork reports. The high-yield debt issue has a 6.25% coupon and is set to mature on October 1, 2040. The debt is now trading at $65.32 On Friday shares of Cliffs Natural Resources Inc.…
-
5 Stocks: VeriSign (NASDAQ:VRSN), Trulia (NYSE:TRLA), ManpowerGroup Inc. (NYSE:MAN), Immunomedics Inc. (NASDAQ:IMMU), NIC Inc. (NASDAQ:EGOV)
VeriSign, Inc. (NASDAQ:VRSN) announced that its earnings call for the fourth quarter and full year 2014 will take place on Thursday, Feb. 5, 2015, at 4:30 p.m. (EST). On Thursday shares of VeriSign, Inc. (NASDAQ:VRSN) closed at $55.57. Company’s sales growth for last 5 years was 11.50% and EPS growth for next 5 years is…
-
Must Watch These 5 Stocks: Applied Materials (NASDAQ:AMAT), Immunomedics Inc. (NASDAQ:IMMU), Pfizer (NYSE:PFE), Ford Motor (NYSE:F), Alexandria Real Estate Equities (NYSE:ARE)
Applied Materials, Inc. (NASDAQ:AMAT) declared a quarterly dividend, which is scheduled for Wednesday, March 11th. Investors of record on Wednesday, February 18th will be given a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.60%. The ex-dividend date of this dividend is Friday, February 13th.…
-
Pre-market Gainers to Watch: Conatus Pharmaceuticals Inc. (NASDAQ:CNAT), Immunomedics Inc. (NASDAQ:IMMU), El Pollo Loco Holdings (NASDAQ:LOCO), Isis Pharmaceuticals (NASDAQ:ISIS)
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) announced that it will report top-line results from three clinical trials in subjects with varying degrees of organ impairment – the company’s Phase 2 trial in patients with acute-on-chronic liver failure (ACLF), Phase 1 trial in patients with mild, moderate and severe hepatic impairment, and Phase 1 trial in patients with…
-
Top News: Athersys (NASDAQ:ATHX), Immunomedics Inc. (NASDAQ:IMMU), Apple Inc. (NASDAQ:AAPL), PBF Logistics LP (NYSE:PBFX), Woodward (NASDAQ:WWD)
Athersys, Inc. (NASDAQ:ATHX) announced that it has concluded patient enrollment of its Phase 2 clinical study involving administration of Athersys’ MultiStem(R) cell therapy to ischemic stroke patients. The study is a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the safety and efficacy of MultiStem therapy in subjects suffering moderate to moderate-severe ischemic strokes. Athersys, Inc.…
-
Why Traders Are Watching: Immunomedics Inc. (NASDAQ:IMMU), ARMOUR Residential REIT (NYSE:ARR), Radian Group (NYSE:RDN), Poage Bankshares, (NASDAQ:PBSK), Willamette Valley Vineyards (NASDAQ:WVVI)
Immunomedics (NASDAQ:IMMU) Director Mary E. Paetzold unloaded 10,000 shares of the company’s stock on the open market in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $4.71, for a total transaction of $47,100.00. Following the completion of the transaction, the director now directly owns 50,415 shares…